SARS-CoV-2 Vaccines: Status Report.
Immunity
; 52(4): 583-589, 2020 04 14.
Article
in English
| MEDLINE | ID: covidwho-20439
ABSTRACT
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Viral Vaccines
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
/
Drug Development
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Animals
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Immunity
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
J.immuni.2020.03.007
Similar
MEDLINE
...
LILACS
LIS